Ocular therapeutix, inc. (OCUL)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-21,512

26,017

18,778

58,701

-17,124

17,399

15,010

13,804

13,765

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-15,567

-18,694

-16,023

-

-9,596

-11,445

-10,840

-10,637

-11,524

-10,009

-7,578

-7,954

-7,294

-6,392

-7,008

Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense

1,665

1,953

3,169

1,695

1,942

1,949

1,873

1,830

1,831

2,109

1,750

1,757

1,705

1,723

1,369

1,515

1,349

1,336

1,231

1,152

921

977

607

557

503

Licensing and consultant fees paid in common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

2,364

Non-cash interest expense

1,048

1,214

1,051

1,009

409

132

80

87

98

99

99

100

110

265

35

36

35

54

38

37

37

37

41

19

6

Amortization of operating lease asset

-

-

-

143

187

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-3,404

-3,024

5,717

-1,606

3,223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization expense

734

674

669

598

589

582

573

566

565

528

482

354

261

253

216

207

205

200

194

187

173

164

139

151

93

Revaluation of preferred stock warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

108

131

141

Purchase of premium on marketable securities

-

-

-

-

-

-

-

-

-

0

0

0

3

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-

-

0

0

6

11

13

20

49

104

-

-

-

-

-

-

-

-

Purchase discount on marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17

-

-

-

-

Amortization of premium on marketable securities, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-148

-21

-18

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable from related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

0

-29

11

Accounts receivable

881

1,434

499

339

75

-39

-45

115

-56

-52

67

-33

-6

7

20

-4

34

4

25

-188

23

276

-7

-216

26

Prepaid expenses and other current assets

234

18

-81

-86

667

642

-151

-34

-197

462

-1,095

-579

1,167

-40

-7

-572

-305

-267

-429

919

-170

-318

305

-59

108

Inventory

153

59

133

497

48

115

-29

-8

17

-5

37

-6

-17

-13

-23

22

-7

-13

2

-13

25

16

8

22

87

Operating lease assets

-188

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-236

92

-742

13

761

207

536

-877

-662

769

-2,759

2,263

659

130

173

-541

79

708

-1,011

498

153

444

-282

41

304

Accrued expenses and deferred rent

-2,617

1,171

1,412

1,022

-1,891

1,599

850

38

-776

-381

627

2,465

-153

1,532

446

-165

-424

-315

914

424

-804

850

654

638

-196

Operating lease liabilities

-260

-248

-286

-64

-246

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-42

-41

-42

-125

62

-

-

-

-

Net cash used in operating activities

-18,854

-19,467

-19,544

-19,181

-19,386

-13,648

-10,873

-12,233

-12,473

-10,383

-14,382

-11,131

-14,577

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,256

-

-9,700

-8,528

-6,879

-5,626

-6,333

-4,512

-4,025

Cash flows from investing activities:
Purchases of property and equipment

249

601

419

493

725

479

473

556

381

564

2,036

3,998

1,654

680

869

243

127

473

76

875

354

441

274

248

297

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

0

0

3,000

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,673

57,511

0

17,500

-

-

-

-

Proceeds from maturities of marketable securities

-

-

-

-

-

-

-

-

-

0

3,000

22,700

12,500

16,000

14,684

25,000

25,000

-

-

-

-

-

-

-

-

Net cash used in investing activities

-249

-601

-419

-493

-725

-479

-473

-556

-381

-564

969

18,702

7,846

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

24,873

-

-27,587

8,958

-17,854

-37,767

-274

-248

-297

Cash flows from financing activities:
Proceeds from issuance of notes payable

-

-

-

-

-

-

-

-

-

0

0

0

3,700

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of 2026 convertible notes, net of issuance costs

-

0

0

-70

37,345

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of stock options

128

44

33

0

1

51

73

7

266

506

141

36

2

46

78

70

5

32

31

110

34

7

4

3

21

Proceeds from issuance of common stock upon public offering, net

12,690

8,890

18,579

5,114

4,954

5,610

12,843

8,128

34,990

581

1,585

800

26,272

-

-

-

-

-

-

-

-

-

-

-

-

Payments of insurance costs financed by a third party

-

-

-

-

-

-

-

-

-

0

197

197

197

130

0

195

194

222

198

171

171

-

-

-

-

Repayment of notes payable

-

-

-

-

-

1,543

1,543

1,542

1,029

0

0

0

1,300

-

-

-

-

-

-

-

-

0

0

1,819

454

Net cash provided by financing activities

12,818

9,091

18,612

5,338

42,300

16,328

11,373

6,712

34,227

1,206

1,529

796

28,477

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-6,285

-10,977

-1,351

-14,336

22,189

2,201

27

-6,077

21,373

-9,741

-11,884

8,367

21,746

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-189

-

-201

65,733

-137

-106

67,555

11,954

-433

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,064

1,958

15,428

-10,414

-37,488

66,163

-24,870

-43,499

60,948

7,194

-4,755

Supplemental disclosure of cash flow information:
Cash paid for interest

585

-

-

-

475

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

318

316

164

46

Supplemental disclosure of non-cash investing and financing activities:
Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5

6

Additions to property and equipment included in accounts payable and accrued expenses at balance sheet dates

21

-250

199

89

176

-43

109

-212

301

224

-955

282

987

317

-54

79

109

-375

534

129

5

129

-47

18

69

Derivative liability in connection with issuance of 2026 convertible notes

-

0

1,749

0

14,685

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering costs included in accounts payable and accrued expenses at balance sheet dates

-

-

-

-

-

31

-9

-265

285

-

-

-

55

-

-

-

-

-

-

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-989

764

326